Current treatment status-Not currently treated Posts on Medivizor

Evaluating the effectiveness and safety of TAS-102 plus Yttrium-90 radioembolization for the treatment of patients with colorectal cancer liver metastasis.

Posted by Medivizor on Oct 22, 2023 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of TAS-102 (Lonsurf; trifluridine-tipiracil) plus Yttrium-90 (Y-90) radioembolization (RE) for patients with colorectal cancer liver metastasis (CRLM) who are unresponsive to chemotherapy. The data showed that TAS-102 plus RE was safe and effective in these patients. Some background...

Evaluating the effectiveness and safety of brentuximab vedotin plus nivolumab consolidation therapy after autologous hematopoietic stem-cell transplantation in patients with high-risk classic Hodgkin lymphoma.

Posted by Medivizor on Aug 27, 2023 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of brentuximab vedotin (BV; Adcetris) plus nivolumab (Opdivo) consolidation therapy after autologous hematopoietic stem-cell transplantation (HSCT) in patients with high-risk relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). The data showed that the BV plus nivolumab combination...

Evaluating the effectiveness and safety of pembrolizumab for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma before stem cell transplantation.

$Evaluating the effectiveness and safety of pembrolizumab for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma before stem cell transplantation.$

Posted by Medivizor on Jun 11, 2023 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of pembrolizumab (Keytruda) for the treatment of patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL) before stem cell transplantation. The data showed that pembrolizumab was effective and safe with manageable side effects in these patients. Some background...

Evaluating the effectiveness and safety of sacituzumab govitecan versus chemotherapy in patients with HR+, HER2– metastatic breast cancer.

Posted by Medivizor on Apr 23, 2023 in Breast cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of sacituzumab govitecan (Trodelvy; SG) compared to chemotherapy in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (BC). The data showed that SG significantly improved survival without cancer progression compared to chemotherapy in these...

Evaluating the effectiveness of abemaciclib alone or in combination with tamoxifen in patients with HR+, HER2– metastatic breast cancer resistant to hormone therapy.

Posted by Medivizor on Jan 8, 2023 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness of abemaciclib (Verzenio) alone or in combination with tamoxifen (Nolvadex) in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (BC) resistant to hormone therapy. The data showed that abemaciclib in combination with tamoxifen was more effective in improving...

Ibrutinib and venetoclax treatment for patients with relapsed or refractory chronic lymphocytic leukemia according to minimal residual disease status.

$Ibrutinib and venetoclax treatment for patients with relapsed or refractory chronic lymphocytic leukemia according to minimal residual disease status.$

Posted by Medivizor on Dec 4, 2022 in Leukemia | 0 comments

In a nutshell This study investigated the effectiveness and safety of time-limited treatment with ibrutinib (Imbruvica) plus venetoclax (Venclexta) for patients with relapsed or refractory (r/r) chronic lymphocytic leukemia (CLL) by using minimal residual disease (MRD) guidance. The data showed that time-limited treatment with ibrutinib plus venetoclax...

Evaluating the long-term effectiveness of fixed-duration treatment with venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.

$Evaluating the long-term effectiveness of fixed-duration treatment with venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.$

Posted by Medivizor on Nov 22, 2022 in Leukemia | 0 comments

In a nutshell This study evaluated the long-term effectiveness of fixed-duration treatment with venetoclax (Venclexta) plus rituximab (Rituxan) in patients with relapsed or refractory (r/r) chronic lymphocytic leukemia (CLL). The data showed that fixed-duration treatment with venetoclax plus rituximab was effective over the long term in these...

Evaluating ponatinib treatment in any phase of treatment in patients with chronic myeloid leukemia resistant or intolerant to other tyrosine kinase inhibitors

Posted by Medivizor on Sep 18, 2022 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of ponatinib (Iclusig) in patients with chronic myeloid leukemia (CML) who were resistant or intolerant to previous tyrosine kinase inhibitors (TKIs). This study concluded that ponatinib was effective in heavily pretreated patients when administered in any phase of...

Evaluating outcomes after salvage therapy using chemotherapy or allogeneic stem cell transplantation for unresponsive acute myeloid leukemia

Posted by Medivizor on Sep 17, 2022 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the impact of salvage treatment using either chemotherapy (CT) or allogeneic hematopoietic stem cell transplant (allo-HSCT) on the overall outcome in patients with refractory (unresponsive) acute myeloid leukemia (AML). This study concluded that allo-HSCT benefits these patients and that direct...

Evaluating the effectiveness of a second autologous hematopoietic cell transplantation performed with stem cells obtained after previous transplantation in patients with relapsed multiple myeloma.

Posted by Medivizor on Jul 16, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness of salvage autologous hematopoietic cell transplantation (ASCT) performed with stem cells obtained after previous transplantation in patients with relapsed multiple myeloma (MM). The data showed that salvage ASCT performed with stem cells remobilized after previous transplantation is a good treatment...

Evaluating the effectiveness and safety of isatuximab in combination with pomalidomide and low-dose dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma.

$Evaluating the effectiveness and safety of isatuximab in combination with pomalidomide and low-dose dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma.$

Posted by Medivizor on Jun 26, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the long-term effectiveness and safety of isatuximab (Sarclisa) in combination with pomalidomide (Pomalyst) and low-dose dexamethasone (Decadron) (Pd) in previously treated patients with relapsed or refractory (r/r) multiple myeloma (MM). The data showed that isatuximab plus Pd combination significantly improved the...

Evaluating brentuximab-vedotin with bendamustine combination treatment before transplantation in patients with relapsed/refractory Hodgkin lymphoma

$Evaluating brentuximab-vedotin with bendamustine combination treatment before transplantation in patients with relapsed/refractory Hodgkin lymphoma$

Posted by Medivizor on Jun 1, 2022 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of brentuximab-vedotin (Bv; Adcetris) combined with bendamustine (Treanda: B) as salvage treatment in patients with relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). This study concluded that this treatment is safe and effective in these patients....

Current treatment status-Not currently treated Posts on Medivizor

Evaluating the effectiveness and safety of TAS-102 plus Yttrium-90 radioembolization for the treatment of patients with colorectal cancer liver metastasis.

Evaluating the effectiveness and safety of brentuximab vedotin plus nivolumab consolidation therapy after autologous hematopoietic stem-cell transplantation in patients with high-risk classic Hodgkin lymphoma.

Evaluating the effectiveness and safety of pembrolizumab for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma before stem cell transplantation.

Evaluating the effectiveness and safety of sacituzumab govitecan versus chemotherapy in patients with HR+, HER2– metastatic breast cancer.

Evaluating the effectiveness of abemaciclib alone or in combination with tamoxifen in patients with HR+, HER2– metastatic breast cancer resistant to hormone therapy.

Ibrutinib and venetoclax treatment for patients with relapsed or refractory chronic lymphocytic leukemia according to minimal residual disease status.

Evaluating the long-term effectiveness of fixed-duration treatment with venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.

Evaluating ponatinib treatment in any phase of treatment in patients with chronic myeloid leukemia resistant or intolerant to other tyrosine kinase inhibitors

Evaluating outcomes after salvage therapy using chemotherapy or allogeneic stem cell transplantation for unresponsive acute myeloid leukemia

Evaluating the effectiveness of a second autologous hematopoietic cell transplantation performed with stem cells obtained after previous transplantation in patients with relapsed multiple myeloma.

Evaluating the effectiveness and safety of isatuximab in combination with pomalidomide and low-dose dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma.

Evaluating brentuximab-vedotin with bendamustine combination treatment before transplantation in patients with relapsed/refractory Hodgkin lymphoma

Categories

Recent Posts

Archives

Current treatment status-Not currently treated Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email